Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health

VIENNA - Saturday, 25. April 2026

(BUSINESS WIRE) -- Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages.

Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.”

The Product in Dispute

The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into an innovative treatment for rare blood cancers, particularly polycythemia vera, through a comprehensive clinical trial program. This makes BESREMi® the best investigated interferon in clinical trials in this indication as documented in the major relevant guidelines2. AOP Health had acquired the rights for both BESREMi®’s development and commercialization in the European, Commonwealth of Independent States (CIS), and Middle Eastern markets from PharmaEssentia in 2009. In its seventh year after its approval by European Medicines Agency (“EMA”), AOP Health has successfully made BESREMi® available to an estimated 12,600 patients in AOP Health’s licensed territory.

First Arbitration and Set-aside Proceedings

Since 2017, PharmaEssentia repeatedly attempted to terminate its agreement with AOP Health regarding BESREMi®. In October 2020, an ICC Arbitral Tribunal rejected these attempts and awarded AOP Health approx. EUR 143 million in damages and dismissed PharmaEssentia’s counterclaims in its entirety.

Subsequent set-aside proceedings confirmed the arbitral award in its essentials, but found procedural flaws with respect to damage quantification, impacting the damages awarded.

Second Arbitration

In November 2020, PharmaEssentia initiated a legal action against AOP Health, alleging damage claims. AOP Health in turn claimed damages for delays in BESREMi®’s European approval caused by PharmaEssentia, and the misuse of AOP Health’s clinical trial data for PharmaEssentia’s US marketing authorization. The result was a partial final ICC arbitral award in favor of AOP Health, received on 17 February 2025, which found PEC guilty of intentional breaches and liable for several claims. The tribunal’s decision on the quantum of those claims is yet to be made.

Ruling of Higher Regional Court of Frankfurt Confirms AOP Health’s Position

In May 2025, PharmaEssentia filed an application with the Frankfurt Higher Regional Court to set aside the partial final ICC arbitral award dated 10 February 2025, arguing among other things that the award violated public order and PharmaEssentia’s right to be heard.

On 24 April 2026, the Frankfurt Higher Regional Court dismissed this application in its entirety and declared the award enforceable. An appeal to the German Federal Court of Justice is possible.

AOP Health believes this decision confirms its position and reinforces its commitment to patients. The company will continue to supply patients in need of ropeginterferon alfa-2b (BESREMi®), maintaining the high standards of quality patients depend on.

About BESREMi®

BESREMi® is the first interferon that was approved for polycythemia vera, a myelo­proliferative neoplasm (MPN), indicated in the European Union as monotherapy in adults for treatment of polycythemia vera without symptomatic enlarged spleen. Its overall safety and efficacy were demonstrated in multiple clinical studies.

BESREMi® (ropeginterferon alfa-2b) is a long-acting, mono-pegylated proline interferon (ATC L03AB15). It is administered once every 2 weeks initially, or up to every 4 weeks after stabilization of blood values. BESREMi® is designed to be self-administered subcutaneously with a pre-filled pen.

For the EMA Summary of Product Characteristics please visit: BESREMi®

About AOP Health

AOP Health is a global healthcare group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH ("AOP Health") is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine.

At the end of 2024, AOP Health received its first U.S. FDA approval for RapiblykTM, a medication aimed at patients in intensive care units, thereby further strengthening its commitment to making therapies available for patients worldwide. The AOP Health Group has established itself internationally as a pioneer in integrated therapy solutions and operates worldwide through subsidiaries, representations, and a strong network of partners.

With the claim "Needs. Science. Trust." the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the AOP Health Group’s actions.

1 https://www.aop-health.com/global_en/press/press-releases/icc-arbitral-tribunal-ruling-aop-health/

2 ELN Guideline (2022), NCCN Guideline (2024), Onkopedia Leitlinie (2023)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260424005227/en/

Permalink

https://www.aetoswire.com/en/news/2504202654551

Contacts

Further inquiry

Nina Roth

Nina.Roth@aop-health.com

+43-676-3131509

SLB Announces First-Quarter 2026 Results

 

HOUSTON - 

SLB (NYSE: SLB) is a global technology company that has driven energy innovation for 100 years. With a global presence in more than 100 countries and employees representing almost twice as many nationalities, we work each day on innovating oil and gas, delivering digital at scale, decarbonizing industries, and developing and scaling new energy systems that accelerate the energy transition. Find out more at slb.com.

Conference Call Information

SLB will hold a conference call to discuss the earnings press release and business outlook on Friday, April 24, 2026. The call is scheduled to begin at 11:00 a.m. U.S. Eastern time. To access the call, which is open to the public, please contact the conference call operator at +1 (833) 470-1428 within North America, or +1 (404) 975-4839 outside of North America, approximately 10 minutes prior to the call’s scheduled start time, and provide the access code 742955. At the conclusion of the conference call, an audio replay will be available until May 1, 2026, by dialling +1 (866) 813-9403 within North America, or +1 (929) 458-6194 outside of North America, and providing the access code 360731. The conference call will be webcasted simultaneously at https://events.q4inc.com/attendee/972985185 on a listen-only basis. A replay of the webcast will also be available at the same website until May 1, 2026.

Forward-Looking Statements

This first-quarter 2026 earnings press release, as well as other statements we make, contain “forward-looking statements” within the meaning of the federal securities laws, which include any statements that are not historical facts. Such statements often contain words such as “expect,” “may,” “can,” “believe,” “predict,” “plan,” “potential,” “projected,” “projections,” “precursor,” “forecast,” “outlook,” “expectations,” “estimate,” “intend,” “anticipate,” “ambition,” “goal,” “target,” “scheduled,” “think,” “should,” “could,” “would,” “will,” “see,” “likely,” and other similar words. Forward-looking statements address matters that are, to varying degrees, uncertain, such as statements about our financial and performance targets and other forecasts or expectations regarding, or dependent on, our business outlook; growth for SLB as a whole and for each of its Divisions (and for specified business lines, geographic areas, or technologies within each Division); the benefits of the ChampionX acquisition, including the ability of SLB to integrate the ChampionX business successfully and to achieve anticipated synergies and value creation from the acquisition; oil and natural gas demand and production growth; oil and natural gas prices; forecasts or expectations regarding energy transition and global climate change; improvements in operating procedures and technology; capital expenditures by SLB and the oil and gas industry; our business strategies, including digital and “fit for basin,” as well as the strategies of our customers; our capital allocation plans, including dividend plans and share repurchase programs; our APS projects, joint ventures, and other alliances; the impact of the ongoing or escalating conflicts on global energy supply; access to raw materials; future global economic and geopolitical conditions; future liquidity, including free cash flow; and future results of operations, such as margin levels. These statements are subject to risks and uncertainties, including, but not limited to, changing global economic and geopolitical conditions; changes in exploration and production spending by our customers, and changes in the level of oil and natural gas exploration and development; the results of operations and financial condition of our customers and suppliers; the inability to achieve our financial and performance targets and other forecasts and expectations; the inability to achieve our net-zero carbon emissions goals or interim emissions reduction goals; general economic, geopolitical, and business conditions in key regions of the world; foreign currency risk; inflation; changes in monetary policy by governments; tariffs; pricing pressure; weather and seasonal factors; unfavorable effects of health pandemics; availability and cost of raw materials; operational modifications, delays, or cancellations; challenges in our supply chain; production declines; the extent of future charges; the inability to recognize efficiencies and other intended benefits from our business strategies and initiatives, such as digital or new energy, as well as our cost reduction strategies; changes in government regulations and regulatory requirements, including those related to offshore oil and gas exploration, radioactive sources, explosives, chemicals, and climate-related initiatives; the inability of technology to meet new challenges in exploration; the competitiveness of alternative energy sources or product substitutes; and other risks and uncertainties detailed in this press release and our most recent Forms 10-K, 10-Q, and 8-K filed with or furnished to the Securities and Exchange Commission (the “SEC”).

If one or more of these or other risks or uncertainties materialize (or the consequences of any such development changes), or should our underlying assumptions prove incorrect, actual results or outcomes may vary materially from those reflected in our forward-looking statements. Forward-looking and other statements in this press release regarding our environmental, social, and other sustainability plans and goals are not an indication that these statements are necessarily material to investors or required to be disclosed in our filings with the SEC. In addition, historical, current, and forward-looking environmental, social, and sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future. Statements in this press release are made as of the date of this release, and SLB disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events, or otherwise.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260422463846/en/

Permalink

https://aetoswire.com/en/news/2404202654545

Contacts

Investors

James R. McDonald — SVP, Investor Relations & Industry Affairs, SLB

Joy V. Domingo — Director of Investor Relations, SLB

Tel: +1 (713) 375-3535

investor-relations@slb.com

Media

Josh Byerly — SVP of Global Communications, SLB

Moira Duff — Director of External Communications, SLB

Tel: +1 (713) 375-3407

media@slb.com

PMC Organometallix Announces Price Increase on All Products

 (BUSINESS WIRE) -- Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%.

This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges.

Customers with questions or to discuss a specific situation should contact their account representative.

About PMC Group

PMC Group is a growth-oriented, diversified, global chemicals and plastics company delivering innovative solutions to everyday needs in a broad range of end markets including plastics, consumer products, electronics, paints, packaging, mining, personal care, food, automotive and pharmaceuticals. PMC was built on a sustainable model of growth through innovation while promoting social good. Dedicated to sustainability, PMC derives over half of its raw materials from renewable sources, operating from a worldwide network across the Americas, Europe and Asia. Learn more at www.pmc-group.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260424142135/en/

Permalink

https://aetoswire.com/en/news/2504202654555

Contacts

Jeff Hammerstrom

jeff.hammerstrom@pmc-group.com

Customer Service: Americas 855-638-2549, EMEA +0031(0)85 9024966

 

Gamma Waves Launches: Playing Tomorrow’s Game Today

 (BUSINESS WIRE) -- Gamma Waves, a permanent capital investment company, with the ambition to build an innovative sport-focused platform, launches today. Based in Amsterdam, the company was founded by Andrea Agnelli, Rocco Benetton and Giorgio Chiellini, with the aim of creating new value across:

Sport IPs (Intellectual Properties): assets in globally captivating sectors such as basketball, hockey, cricket, tennis, baseball, rugby, etc., offering unique reach and credibility;

Sports Tech: high-quality sports technology products that often struggle to scale because, on their own, they lack sufficient incentives and distribution to break through alongside IPs.

Gamma Waves aims to bridge this gap by building a multi-franchise platform and using it, selectively and responsibly, as an accelerator for the growth of the Sports Tech portfolio.

A simple belief underpins this endeavour. The game has changed and the next era of sports will be shaped by those who can connect what has historically lived apart. A simple game became a global product; today it is becoming digital, immersive and personalised, driven by new generations, new formats, and a world in which athletes, creators and communities shape attention every day.

“Sport is one of the few things that people truly feel,” said Andrea Agnelli, Founder of Gamma Waves, “but the way people experience it is dramatically changing. Tomorrow’s game is unconventional and it needs an unconventional approach. Our ambition is to drive innovation while honouring the legacy and cultural significance of sport. In doing so, we aim to create a virtuous cycle of value across both.”

Gamma Waves is deeply rooted in sport and founded on a clear conviction: the most compelling value is created at the intersection of Sports IP and Sports Tech, reshaping how sport is played, consumed and monetised. The firm will take minority stakes in forward-looking competitions, clubs, teams, athletes and emerging formats, while also investing in growth-stage sports-tech companies where adoption is accelerating and impact is measurable: from fan engagement and athlete/team performance to data analytics, AI-automated content production and the connected athlete ecosystem. By linking these investments, Gamma Waves builds a self-reinforcing network: Sports IP-led insight helps select and accelerate technology, and technology, tested, scaled and refined alongside real partners, strengthens IP performance and growth, supported by hands-on execution, aligned incentives, board-level partnership and innovation-driven KPIs.

A different kind of ownership mindset

Gamma Waves will not chase hype cycles. It will build patiently, asset by asset, partnership by partnership, with a long horizon. Investment decisions will be driven by the Chief Investment Officer, Kyang Yung, and selected young talented professionals.

“I am excited to join Andrea, Rocco and Giorgio — three highly complementary individuals whose combined legacy across Sports IP is exceptional. Gamma Waves brings together owners, operators and athletes around the same table, which is powerful and rare. As a tech-minded growth investor, I see a unique opportunity to apply disciplined capital allocation, governance and scaling expertise to assets that sit at the very heart of global culture,” said Chief Investment Officer, Kyang Yung.

What’s next

Following today’s launch, Gamma Waves will focus on:

forming long-term partnerships with forward-looking sports franchises and competition operators,

investing in select companies that strengthen how sport is engaged, measured and experienced, and

building an operating platform that helps partners play tomorrow’s game today without losing authenticity.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260424892627/en/

Permalink

https://aetoswire.com/en/news/2404202654542

Contacts

GAMMA WAVES PARTNERS B.V.

Prinsengracht 769

1017 JZ Amsterdam, The Netherlands

T +31 (0)20 787 1313

www.gammawavespartners.com

Commercial Register No. 99164272

Venture Global Announces Closing of $750,000,000 Senior Secured Notes by Venture Global Calcasieu Pass, LLC

 ARLINGTON, Va. - Friday, 24. April 2026 AETOSWire 

(BUSINESS WIRE) -- Venture Global, Inc. (“Venture Global”, NYSE: VG) announced today that its subsidiary, Venture Global Calcasieu Pass, LLC (“VGCP”) has closed an offering of $750,000,000 aggregate principal amount of 6.000% senior secured notes due 2036 (the “Notes”). The Notes will mature on May 1, 2036.

VGCP used the net proceeds from the offering, together with cash on hand and proceeds received from certain hedge terminations, for the prepayment, in full, of VGCP’s outstanding term loans, and to pay fees and expenses in connection with the offering. The Notes are guaranteed by TransCameron Pipeline, LLC (VGCP’s affiliate). The Notes are secured on a pari passu basis by a first-priority security interest in the assets that secure VGCP’s existing senior secured first lien credit facilities and VGCP’s existing senior secured notes.

The Notes were not registered under the Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state or other jurisdictions, and the Notes may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the Notes, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale of these securities would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Venture Global

Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in the United States. The company’s vertically integrated business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. Venture Global’s first three projects, Calcasieu Pass, Plaquemines LNG, and CP2 LNG, are located in Louisiana along the Gulf of America. Venture Global is developing Carbon Capture and Sequestration projects at each of its LNG facilities.

Forward-Looking Statements

This press release contains certain statements that may include “forward-looking statements.” All statements, other than statements of historical or present facts or conditions, included herein are “forward-looking statements.” Included among “forward-looking statements” are, among other things, statements regarding Venture Global’s business strategy, plans and objectives, including the use of proceeds from the offering. Venture Global believes that the expectations reflected in these “forward-looking statements” are reasonable, they are inherently uncertain and involve a number of risks and uncertainties beyond Venture Global’s control. In addition, assumptions may prove to be inaccurate. Actual results may differ materially from those anticipated or implied in “forward-looking statements” as a result of a variety of factors. These “forward-looking statements” speak only as of the date made, and other than as required by law, Venture Global undertakes no obligation to update or revise any “forward-looking statement” or provide reasons why actual results may differ, whether as a result of new information, future events or otherwise.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260423774519/en/

Permalink

https://www.aetoswire.com/en/news/2404202654514

Contacts

Investor Contact

Ben Nolan

IR@ventureglobalLNG.com

Media Contact

Shaylyn Hynes

press@ventureglobalLNG.com

NIQ and INTAGE HD Partner to Expand Retail Measurement Across Japan and Global Markets

 (BUSINESS WIRE)--NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, and INTAGE HOLDINGS Inc. (hereafter "INTAGE HD"), a leading market research company in Japan, today announced a mutual sales partnership to expand access to retail measurement insights between Japan and global markets.

Through the collaboration, NIQ and INTAGE HD bring together complementary strengths— INTAGE HD’s deep local retail store panel data and insights into the Japanese domestic market, and NIQ’s global and regional retail store panel data and insights into various international markets—to enable better comparison and understanding of market performance and trends across countries and regions.

This collaboration enhances both companies’ ability to support clients with more consistent and comparable insights, helping clients unlock growth opportunities across markets.

The collaboration enables global clients to access INTAGE HD’s nationwide retail store panel data in Japan (SRI+ and SRI+EC) to support market entry and expansion. NIQ's network will enable smoother access to data and insights on the Japanese market. At the same time, clients in Japan will gain access to NIQ’s global Retail Measurement Services (RMS), covering more than 100 countries and regions, supporting international growth.

“Clients today are increasingly looking for a more complete and connected understanding of consumer buying behavior across markets,” said Chang Park, Managing Director of NIQ’s Northeast Asia Cluster. “Our collaboration with INTAGE HD strengthens our ability to deliver The Full View™—bringing together local depth and global scale to help clients unlock new opportunities and drive growth.”

This collaboration addresses a key challenge for clients: limited comparability between Japan and other markets by connecting local and global data more seamlessly.

Whether expanding into Japan or growing in international markets, clients will benefit from a more unified view of performance.

“Japan is a highly complex and unique market, and a deep understanding of the local market and a global perspective are both essential to realizing business growth,” said Yoshiya Nishi, CEO of INTAGE HOLDINGS Inc. “Through this collaboration, we will combine the strengths of both companies to provide more consistent and actionable insights in the Japanese and global markets, strongly supporting our clients’ decision-making and growth.”

This collaboration reflects a shared commitment by NIQ and INTAGE HD to help clients navigate increasingly interconnected markets with greater clarity and confidence.

About INTAGE HOLDINGS Inc.

Founded in 1960, the INTAGE Group is a leading marketing research company, ranked No.1 in Asia*. Guided by our vision of “Know today, Power tomorrow,” we leverage massive amounts of data obtained from Japan’s largest consumer panel (SCI) and retail panel (SRI+) to support decision-making across a wide range of industries through data and technology. In recent years, we have increased our support for digital transformation (DX) through data utilization, and accelerated the expansion of our global operations, primarily in Asia, contributing to the creation of a sustainable society.

* Based on ESOMAR’s Global Top-50 Insights Companies 2025 (in terms of the Group’s consolidated net sales).

About INTAGE Group

(TSE Prime Market stock code: 4326)

Since its founding in 1960, the INTAGE Group has collected, processed, and analyzed a wide range of data, adding unique insights to provide its clients with valuable information and support their decision-making processes. As a partner to our clients, we work closely with them to address their questions, combining consumer insights with technology to guide them toward their next strategic move.

ABOUT NIQ

NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete and trusted understanding of consumer buying behavior and revealing new pathways to growth. By combining an unmatched global data footprint and granular consumer and retail measurement with decades of AI modelling expertise, NIQ builds decision systems that help companies turn complex data into confident action.

With operations in more than 90 countries, NIQ covers approximately 82% of the world’s population and more than $7.4 trillion in global consumer spend. Through cloud-based platforms, advanced analytics and AI-driven insights, NIQ delivers The Full View™—helping brands and retailers understand what consumers buy, why they buy it, and what to do next.

For more information, please visit www.niq.com.

NIQ-GENERAL

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260422378471/en/

Permalink

https://www.aetoswire.com/en/news/54520296

Contacts

Media contacts:

NIQ – liza.martija@nielseniq.com

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results

 ·         Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion

CORRECTION...by Samsung Epis Holdings

 

(BUSINESS WIRE) -- Third paragraph, second sentence of release should read: Revenue and operating profit in the first quarter increased by 14% (KRW 54.3 billion) and 13% (KRW 16.1 billion) in year-over-year (YoY), respectively. (instead of Revenue and operating profit in the fourth quarter increased by 14% (KRW 54.3 billion) and 13% (KRW 16.1 billion) in year-over-year (YoY), respectively.).

The updated release reads:

SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026.

“Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10^th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.”

First Quarter 2026 Results

On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KRW 454.9 billion with an operating profit of KRW 144.0 billion. Revenue and operating profit in the first quarter increased by 14% (KRW 54.3 billion) and 13% (KRW 16.1 billion) in year-over-year (YoY), respectively.

First quarter growth surpassed the January 2025 guidance by more than 10%, reflecting stronger-than-expected performance across the business.

Samsung Epis Holdings posted a consolidated revenue of KRW 453.9 billion and operating profit of KRW 90.5 billion. Non-cash accounting adjustments, including amortization of purchase price allocation (PPA)-related development costs, are reflected in consolidated revenue and operating profit, following a consolidated revenue of KRW 251.7 billion and operating loss of KRW 63.6 billion in November and December 2025.

[Samsung Bioepis Earnings, KRW billion]
	Q1’24	Q1’25	Q1’26		YoY Change
Revenue	280.1	400.6	454.9		+54.3 (+14%)
Operating Profit	38.1	127.9	144.0		+16.1 (+13%)

Business Updates

·         In October 2025, Samsung Bioepis entered into a private label partnership with CVS Caremark, the Pharmacy Benefit Manager (PBM) division of CVS Health, for OSPOMYV™ (denosumab-dssb), a biosimilar to Prolia¹.

·         BENEPALI™ (etanercept), Samsung Bioepis’ first biosimilar in Europe, continues to maintain its leadership position in the market as it celebrates its 10^th anniversary in Europe.

·         In March, Samsung Bioepis expanded its development and commercialization partnership with Sandoz, on up to five biosimilar candidates including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), in multiple markets.

·         Also in March, a Phase 1 first-in-human clinical trial for Samsung Bioepis’s first novel antibody-drug conjugate (ADC) candidate, SBE303, has begun. Following the announcement, the company also presented a poster presentation of its nonclinical data at the American Association for Cancer Research (AACR) 2026 on April 20^th which demonstrates its encouraging efficacy, safety, tolerability and a promising ability to work in combination with existing immuno-oncology therapies.

·         Samsung Bioepis’s second novel ADC candidate, SBE313, is currently in nonclinical development in collaboration with Phrontline Biopharma.

Disclaimer

This document contains ‘forward-looking statements’ regarding future expectations, projections, plans, and anticipation. ‘Forward-looking statements’ are matters that pertain to the Company’s future business and financial performance, and are subject to uncertainties such as trends in domestic and international financial markets, including but not limited to fluctuations in exchange rates and/or interest rates.

‘Forward-looking statements,’ by their nature, addresses matters that may be uncertain; actual results may be materially different from those expressed in this document.

About Samsung Epis Holdings Co., Ltd.

As an investment holdings company dedicated to biopharmaceuticals and biotechnology, Samsung Epis Holdings aims to maximize corporate and shareholder value through proactive R&D and investment and optimize business strategies for its subsidiaries, Samsung Bioepis and Epis NexLab. Samsung Epis Holdings continues to embrace future challenges and drive innovation by identifying new growth drivers and strengthening global collaboration platforms, thereby laying a solid foundation for the continued growth of its subsidiaries. For more information about Samsung Epis Holdings, please visit: www.samsungepisholdings.com.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.

About Epis NexLab Co., Ltd.

Established in 2025 as a 100% owned subsidiary of Samsung Epis Holdings, Epis NexLab is committed to driving innovation through the development of next-generation biotechnology platforms. By transforming highly scalable peptide-related technologies into development platforms, Epis NexLab is focused on the discovery of innovative treatment modalities for the development of multiple therapeutic candidates targeting a wide range of diseases. For more information about Epis NexLab, please visit: www.samsungepisholdings.com.

Reference
¹ Prolia is a registered trademark of Amgen Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260422191520/en/

 

Permalink
https://www.aetoswire.com/en/news/2304202654496

 

Contacts

Media Contact
Yoon Kim, yoon1.kim@samsung.com
Anna Nayun Kim, nayun86.kim@samsung.com